Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C†

Cammà, Calogero; Bruno, Savino; Marco, Vito Di; Bona, Danilo Di; Rumi, Maria Grazia; Vinci, M.; Rebucci, Chiara; Cividini, Agostino; Pizzolanti, Giuseppe; Minóla, E.; Mondelli, Mario U.; Colombo, Massimo; Pinzello, G.; Craxı̀, Antonio

doi:10.1002/hep.20983

Cited by 151 publications

(126 citation statements)

References 43 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…Other mechanisms involving Tumour Necrosis Factor-a (TNF-a), development of hepatic steatosis and iron overload causing insulin resistance, lack of phosphatidylinositol (PI)-3 kinase activation have also been reported [20][21][22]. However, our study did not look into the aspect of pathogenesis causing IGT/ DM in our patients.…”

Section: Discussionmentioning

confidence: 70%

To Study the Prevalence of Impaired Glucose Tolerance in Patients with Hepatitis C Virus Related Chronic Liver Disease

Kaur

Singh

Pannu

et al. 2015

JCDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 70%

To Study the Prevalence of Impaired Glucose Tolerance in Patients with Hepatitis C Virus Related Chronic Liver Disease

Kaur

Singh

Pannu

et al. 2015

JCDR

View full text Add to dashboard Cite

“…As well as predisposing to T2DM, the presence of IR in CHC predicts non-response to antiviral therapy [26] , both for genotype 1 [26,[34][35][36] and genotypes 2 and 3 infection [37] . Central obesity, which can be associated with IR, has also been shown to predict non-response [38] .…”

Section: Complications Of Hcv-induced Irmentioning

confidence: 99%

Molecular mechanisms of insulin resistance in chronic hepatitis C

Douglas

George²

2009

WJG

View full text Add to dashboard Cite

It is now widely recognized that chronic hepatitis C (CHC) is associated with insulin resistance (IR) and type 2 diabetes, so can be considered a metabolic disease. IR is most strongly associated with hepatitis C virus (HCV) genotype 1, in contrast to hepatic steatosis, which is associated with genotype 3 infection. Apart from the well-described complications of diabetes, IR in CHC predicts faster progression to fibrosis and cirrhosis that may culminate in liver failure and hepatocellular carcinoma. More recently, it has been recognized that IR in CHC predicts a poor response to antiviral therapy. The molecular mechanisms for the association between IR and HCV infection are not well defined. This review will elaborate on the clinical associations between CHC and IR and summarize current knowledge regarding the molecular mechanisms that potentially mediate HCV-associated IR.

show abstract

“…Further exploration is needed to clarify the complex context of MS with respect to different ethnicity. Furthermore, emerging lines of clinical data revealed that several metabolic disturbance; such as obesity, IR, and hepatic steatosis, are significant risk factors for decreased treatment response to pegylated IFN (PegIFN) and ribavirin combination therapy in CHC patients (Bressler et al, 2003;Camma et al, 2006;RomeroGomez et al, 2005;Watanabe et al, 2008). The association between HCV infection and MS could be validated by the sequential changes of MS characteristics upon treatment response to antiviral therapy.…”

Section: Metabolic Disordersmentioning

confidence: 99%